NCT02663193View on ClinicalTrials.gov

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability

CompletedOBSERVATIONAL

Enrollment

108

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Prostate Cancer

Interventions

OTHER

No Intervention

Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.

Trial Locations (20)

Unknown

Homewood

La Mesa

Wheat Ridge

Daytona Beach

Indianapolis

Jeffersonville

Saint Clair Shores

Englewood

Lawrenceville

Morristown

Poughkeepsie

Syracuse

Middleburg Heights

Springfield

Bala-Cynwyd

Lancaster

Charleston

Myrtle Beach

San Antonio

Virginia Beach

All Listed Sponsors

lead

Janssen Scientific Affairs, LLC

INDUSTRY

NCT02663193 - Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability | Biotech Hunter | Biotech Hunter